What is the best antidepressant for a middle‑aged adult with severe three‑vessel coronary artery disease who has refused coronary artery bypass grafting, has a baseline QTc interval of 466 ms, and requires close cardiac monitoring?

Best Antidepressant for Severe CAD with Prolonged QTc

For this patient with severe three-vessel coronary artery disease and a QTc of 466 ms, sertraline is the best antidepressant choice, as it has demonstrated both cardiac safety and efficacy in patients with coronary artery disease while having minimal QT-prolonging effects compared to other SSRIs.

Primary Recommendation

Start sertraline at 50 mg daily, with close QTc monitoring given the baseline borderline prolongation (466 ms). 1, 2, 3

Why Sertraline Over Other Options

• Proven cardiac safety: Multiple high-quality trials specifically in CAD populations demonstrate sertraline's safety profile 2, 4
• Minimal QT effects: Unlike citalopram and escitalopram, sertraline does not carry FDA dose restrictions due to QT prolongation 5
• Evidence-based efficacy: Sertraline is one of only two SSRIs (along with citalopram) clearly more effective than placebo in moderate-to-severe depression in CHD patients 2

Critical Medications to Avoid

Absolutely Contraindicated:

• Tricyclic antidepressants (TCAs): These cause hypotension, worsen heart failure, prolong QT interval, delay AV-node conduction, and increase cardiac arrest risk (OR 1.69) 1, 5, 6
• Citalopram/Escitalopram: While effective, these have documented QT-prolonging effects with FDA-mandated dose restrictions, making them problematic with your patient's baseline QTc of 466 ms 1, 5

Monitoring Protocol

Given the QTc of 466 ms (borderline prolonged; normal <450 ms in men, <460 ms in women):

1. Baseline ECG: Already done (QTc 466 ms)
2. Repeat ECG:
   • At 1-2 weeks after starting sertraline
   • At steady state (4-6 weeks)
   • With any dose increase
3. Hold or discontinue if: QTc exceeds 500 ms or increases >60 ms from baseline
4. Review drug interactions: Check for other QT-prolonging medications

Alternative Options (If Sertraline Fails or Not Tolerated)

Second-line:

• Mirtazapine: Safe from cardiac perspective in CAD patients, though less robust evidence than sertraline 2, 7

Adjunctive Non-Pharmacological:

• Cognitive behavioral therapy (CBT): Can be combined with sertraline for enhanced effect 3, 4
• Exercise therapy: Beneficial for both depression and cardiovascular health, particularly for mild depression 2, 7

Key Clinical Pitfalls

1. Do not use citalopram/escitalopram despite their proven efficacy in CAD—the QT risk is too high with this patient's baseline QTc of 466 ms 5
2. Avoid TCAs entirely in severe CAD—they worsen heart failure, cause arrhythmias, and increase mortality 1, 6
3. Do not assume all SSRIs are equivalent—they have different cardiac safety profiles 5
4. Monitor QTc serially—baseline prolongation requires ongoing surveillance even with safer agents

Evidence Quality Note

The recommendation for sertraline is supported by multiple RCTs specifically in CAD populations 2, 3, 4, recent 2025 European Heart Journal guidelines 1, and a 2014 European Heart Journal risk stratification framework 5. The CREATE trial 3 and systematic reviews 2, 4 provide the strongest evidence base for sertraline's efficacy and safety in this exact population.